Allspring Global Investments Holdings LLC Has $259.08 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Allspring Global Investments Holdings LLC lessened its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 1.8% in the first quarter, according to its most recent filing with the SEC. The fund owned 1,774,605 shares of the medical research company's stock after selling 33,397 shares during the period. Allspring Global Investments Holdings LLC owned about 3.61% of Charles River Laboratories International worth $259,075,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of CRL. Illinois Municipal Retirement Fund purchased a new stake in shares of Charles River Laboratories International in the fourth quarter valued at $2,510,000. Proficio Capital Partners LLC purchased a new stake in shares of Charles River Laboratories International in the fourth quarter valued at $10,768,000. Versor Investments LP purchased a new stake in shares of Charles River Laboratories International in the fourth quarter valued at $1,094,000. QRG Capital Management Inc. purchased a new stake in shares of Charles River Laboratories International in the fourth quarter valued at $255,000. Finally, Fisher Asset Management LLC lifted its holdings in shares of Charles River Laboratories International by 25.8% in the fourth quarter. Fisher Asset Management LLC now owns 232,318 shares of the medical research company's stock valued at $42,886,000 after purchasing an additional 47,626 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Wall Street Zen lowered Charles River Laboratories International from a "buy" rating to a "hold" rating in a report on Friday. TD Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price objective for the company in a report on Wednesday, May 14th. Mizuho cut their price objective on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a report on Wednesday, April 9th. Evercore ISI upgraded Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price objective for the company in a report on Thursday, May 8th. Finally, Citigroup upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and increased their price objective for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $171.85.

Insider Activity

In other news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the sale, the executive vice president now directly owns 19,513 shares of the company's stock, valued at approximately $2,837,385.33. This trade represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Stock Down 1.1%

Charles River Laboratories International stock traded down $1.68 during mid-day trading on Friday, hitting $149.91. 814,656 shares of the company's stock were exchanged, compared to its average volume of 1,024,364. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. The stock has a market cap of $7.36 billion, a P/E ratio of -230.64, a P/E/G ratio of 5.08 and a beta of 1.48. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $254.15. The stock has a 50 day moving average of $136.13 and a two-hundred day moving average of $153.68.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping the consensus estimate of $2.06 by $0.28. The firm had revenue of $984.17 million for the quarter, compared to the consensus estimate of $942.34 million. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The business's quarterly revenue was down 2.7% on a year-over-year basis. During the same period in the prior year, the business posted $2.27 earnings per share. As a group, analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).